Victoria Hannah
Cardiac precision medicine necessitates accurate disease modeling for effective therapeutic development. Leveraging human stem cells, particularly induced pluripotent stem cells (iPSCs), offers a promising avenue for recapitulating cardiac diseases in vitro. This review explores the current advancements, challenges and future prospects of utilizing iPSC-derived cardiomyocytes for disease modeling, highlighting their potential in elucidating disease mechanisms, screening drug candidates and personalizing treatment strategies.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 